Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
Top stock picks for October
⏸️ Investing
Where to next for the Ramsay Health Care Limited share price?
⏸️ Investing
Will CSL Limited return to $120 per share?
⏸️ Investing
5 growth shares I'd buy with $50,000 today
⏸️ Investing
3 reasons why I'd buy Cochlear Limited shares today
⏸️ Investing
10 blue chips soaring more than 50% in the past year
⏸️ Investing
Where to next for the CSL Limited share price?
⏸️ Investing
Why I think the CSL Limited share price could keep on rising
⏸️ Investing
Why I think Ramsay Health Care Limited is a buy at its 10-year high
⏸️ Investing
Sirtex Medical Limited reports: Is it a buy?
⏸️ Investing
Here's why you need to avoid the stock market (yes, really!)
⏸️ Investing
Ramsay Health Care Limited: One share to buy and hold for the next decade
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
